GLAXF - GlaxoSmithKline plc
| Previous close | 20.26 |
| Open | 20.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 19.96 - 20.00 |
| 52-week range | 14.96 - 24.20 |
| Volume | 424 |
| Avg. volume | 5,809 |
| Market cap | 99.102B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 40.24 |
| EPS (TTM) | 0.50 |
| Earnings date | N/A |
| Forward dividend & yield | 0.93 (4.58%) |
| Ex-dividend date | 14 May 2020 |
| 1y target est | N/A |
- Stockopedia
Will Glaxosmithkline's (LON:GSK) quality and momentum help its shareholders?
The Glaxosmithkline (LON:GSK) share price is currently trading at 1581. But to try and predict what the price will look like in the next 12 months and beyond, ...
- Yahoo Finance UK
Drugs companies pledge £1bn to tackle 'looming' health threats
Big pharma companies including Pfizer, Roche and Bayer hope to bring four new antibiotics to market within the next decade.
- Fool.co.uk
3 top FTSE 100 shares I’d buy in July
These FTSE 100 shares should perform well in the future despite today's uncertain outlook, says Roland Head.The post 3 top FTSE 100 shares I'd buy in July appeared first on The Motley Fool UK.
- Fool.co.uk
£25k to invest? I’d buy these 2 practically invincible FTSE 100 shares
FTSE 100 shares with unbeatable economic moats are the best way to beat the market and build serious wealth, says Tom Rodgers.The post £25k to invest? I'd buy these 2 practically invincible FTSE 100 shares appeared first on The Motley Fool UK.
- Zacks
Pharma Stock Roundup: MRK, AZN Regulatory Updates, GSK's New Coronavirus Deal
Merck (MRK) and AstraZeneca (AZN) provide updates on regulatory applications related to key drugs
- Fool.co.uk
3 UK dividend shares I’d buy today
Many UK companies have suspended or cancelled their dividends in 2020. These three FTSE 100 companies are still paying out income to investors though. The post 3 UK dividend shares I’d buy today appeared first on The Motley Fool UK.
- Zacks
Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.
- Motley Fool
GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact
GlaxoSmithKline (NYSE: GSK) announced Tuesday that Medicago -- a private company owned by Mitsubishi Tanabe Pharma (OTC: MTZXF) and Philip Morris International (NYSE: PM) -- will use GlaxoSmithKline's adjuvant in a COVID-19 vaccine it expects to enter phase 1 trials this month. Medicago's recombinant coronavirus "Virus-Like Particles" will be combined with Glaxo's pandemic adjuvant system to boost immune response, potentially allowing for less antigen per dose and thus, more available vaccine doses.
- Fool.co.uk
Forget Cash ISAs. I’d buy this FTSE 100 company instead
GlaxoSmithKline's shares have underperformed this year and Anna Sokolidou thinks they're a bargain today. Here's why.The post Forget Cash ISAs. I'd buy this FTSE 100 company instead appeared first on The Motley Fool UK.
- Reuters
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal - report
Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported. Clinical trials are due to start in September and Sanofi <SASY.PA> has said it expects to get approval by the first half of next year, sooner than previously anticipated. More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven.
- Fool.co.uk
I think the GSK share price could help you retire early
The GSK share price looks to have the potential to produce large total returns for long-term investors in the years ahead. The post I think the GSK share price could help you retire early appeared first on The Motley Fool UK.
- Fool.co.uk
Forget gold and Bitcoin. I’d buy these 2 crashing UK shares today to make a million
These two UK shares have fallen in the stock market crash and could offer much better return prospects than gold or Bitcoin in my view.The post Forget gold and Bitcoin. I’d buy these 2 crashing UK shares today to make a million appeared first on The Motley Fool UK.
- Fool.co.uk
FTSE 100 shares are cheap! I believe investing in an ISA in July may help you retire rich
July may be a good time to start investing in relatively cheap FTSE 100 (INDEXFTSE: UKX) shares through a Stocks and Shares ISA.The post FTSE 100 shares are cheap! I believe investing in an ISA in July may help you retire rich appeared first on The Motley Fool UK.
- Reuters
GSK says within weeks of resubmitting HIV injection Cabenuva
GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday. ViiV executive Kimberly Smith told a media briefing that the company would stick to its previous guidance of refiling the request around mid-year and that this would happen "within weeks".
- Fool.co.uk
I think the GlaxoSmithKline share price could help you retire early
Invest in GlaxoSmithKline now and you could benefit from a share price recovery, driven by increased sales, profits and a generous quarterly dividend. The post I think the GlaxoSmithKline share price could help you retire early appeared first on The Motley Fool UK.
- Fool.co.uk
Top British stocks for July 2020
We asked our freelance writers to share their top British stocks for July including Prudential, BAE Systems, and Crest Nicholson.The post Top British stocks for July 2020 appeared first on The Motley Fool UK.
- Zacks
GlaxoSmithKline (GSK) Stock Moves -1.39%: What You Should Know
GlaxoSmithKline (GSK) closed at $40.55 in the latest trading session, marking a -1.39% move from the prior day.
- Stockopedia
Stock market volatility: Here's a large-cap worth a closer look
Shares in Glaxosmithkline (LON:GSK) are currently trading at 1633.8 but the question for investors is how much the market chaos of 2020 will impact on its pric...
- Fool.co.uk
Don’t know what stocks to buy? I’d buy cheap FTSE 100 shares in an ISA
Stocks are trading at rock-bottom prices right now. But investor tension means that many are resisting the urge to buy in. Here I look at two FTSE 100 stocks that are too cheap to miss.The post Don't know what stocks to buy? I’d buy cheap FTSE 100 shares in an ISA appeared first on The Motley Fool UK.
- Yahoo Finance UK
Coronavirus: Markets rise on vaccine hopes and lockdown easing in England
French drugmaker Sanofi said it hoped a potential vaccine could be signed off sooner than expected.
- Reuters
Sanofi eyes approval of COVID-19 vaccine by first half of 2021
French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. "We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.
- Zacks
The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern
The Zacks Analyst Blog Highlights: AbbVie, Oracle, GlaxoSmithKline, Kroger and Southern
- Zacks
Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine
Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.
- Fool.co.uk
I think these are the best UK shares to buy for beginner investors
If you're new to investing and want to profit from the stock market crash, these could be the best UK shares to buy now, says Roland Head.The post I think these are the best UK shares to buy for beginner investors appeared first on The Motley Fool UK.
- Reuters
GSK in quest to be best, not first, in race for COVID-19 vaccine
There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline <GSK.L>. The company laid out plans in May to produce 1 billion doses of the efficacy boosters for COVID-19 shots next year, compared to the 700 million or so vaccine doses against a range of diseases it usually produces in a year.
